Conquering Diseases

Study Of An Investigational Drug Combination For Non-Small Cell Lung Cancer

Description

Seeking men and women who have non-small cell lung cancer removed and the cancer tumor has a change in the gene called the PD-L1 gene for a study of an investigational immunotherapy drug added to the usual chemotherapy.

Overview

Participants in this study will be randomly assigned to get the usual chemotherapy for 4 months, the usual chemotherapy for 4 months followed by immunotherapy with the investigational drug for one year, or both the usual chemotherapy and immunotherapy with the investigational drug for 4 months followed by immunotherapy with the investigational drug for 10 months.

What we're hoping for

We are studying whether adding an investigational immunotherapy drug to the usual chemotherapy for non-small lung cancer which has PD-L1 gene changes is better or worse that the usual chemotherapy alone.

Additional Information

ClinicalTrials.gov Identifier: NCT04267848

 Principal Investigator

William  Walsh, MD

UMass Memorial Health Care

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989